Capitalizator.

Capitalize Yourself: Right Data. Real Growth.

Sector Analysis

Pharmaceutical Preparations

Standard Industrial Classification: SIC 2834

Industry Insider Sentiment Analysis

The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.

Filing Date Trade Date Ticker Company Reporting Person Relationship Type Price Qty Total, $ Owned After
2026-04-10 17:42 2026-04-09 PHVS Pharvaris N.V. Modig Berndt Director, Officer SELL $27.74 23,333 $647,281 142,084
2026-04-09 21:38 2026-04-07 ACET Adicet Bio, Inc. ORBIMED ADVISORS LLC 10% owner SELL $6.45 104,658 $674,845 0
2026-04-09 20:30 2026-04-08 RAPP Rapport Therapeutics, Inc. Yeleswaram Krishnaswamy Officer SELL $34.90 360 $12,564 286,516
2026-04-09 20:30 2026-04-08 UTHR UNITED THERAPEUTICS Corp ROTHBLATT MARTINE A Director, Officer OPT+S $580.45 9,500 $5,514,306 40,513
2026-04-09 18:43 2026-04-08 NTHI NEONC TECHNOLOGIES HOLDINGS, INC. Heshmatpour Amir F Director, Officer, 10% owner BUY $5.47 15,000 $82,001 3,032,000
2026-04-09 00:32 2026-04-06 WHWK Whitehawk Therapeutics, Inc. Lennon David James Director, Officer SELL $3.45 260,427 $899,541 533,122
2026-04-08 23:33 2026-04-06 ZLAB Zai Lab Ltd Amado Rafael Officer SELL $20.45 2,739 $56,007 57,022
2026-04-08 23:33 2026-04-06 ZLAB Zai Lab Ltd Chen Yajing Officer SELL $20.45 853 $17,442 31,705
2026-04-08 23:34 2026-04-06 ZLAB Zai Lab Ltd Du Ying Director, Officer SELL $20.45 2,653 $54,249 1,122,626
2026-04-08 23:34 2026-04-06 ZLAB Zai Lab Ltd Edmondson Frazor Titus III Officer SELL $20.45 1,224 $25,028 23,366
2026-04-08 23:34 2026-04-07 CORT CORCEPT THERAPEUTICS INC Guyer William Officer OPT+S $40.97 20,000 $819,400 2,231
2026-04-08 23:35 2026-04-06 ZLAB Zai Lab Ltd Smiley Joshua L Officer SELL $20.45 3,017 $61,692 117,602
2026-04-08 21:20 2026-04-06 PTCT PTC THERAPEUTICS, INC. Boulding Mark Elliott Officer OPT+S $69.45 2,265 $157,293 105,212
2026-04-08 20:39 2026-04-06 KNSA Kiniksa Pharmaceuticals International, plc Moat Ross Officer OPT+S $48.58 2,367 $114,989 12,029
2026-04-08 20:41 2026-04-06 INSM INSMED Inc Lewis William Director, Officer OPT+S $163.22 10,699 $1,746,336 301,185
2026-04-08 20:43 2026-04-06 KNSA Kiniksa Pharmaceuticals International, plc Patel Sanj K Director, Officer OPT+S $50.01 7,278 $363,973 0
2026-04-08 20:51 2026-04-06 AVTX Avalo Therapeutics, Inc. Doyle Mittie Officer OPT+S $18.01 3,970 $71,508 3,622
2026-04-08 20:23 2026-04-06 NUVB Nuvation Bio Inc. Wentworth Kerry Officer OPT+S $4.52 200,000 $903,560 53,000
2026-04-08 20:30 2026-04-06 NUVL Nuvalent, Inc. Porter James Richard Director, Officer OPT+S $103.77 30,000 $3,113,232 324,879
2026-04-08 20:33 2026-04-07 UTHR UNITED THERAPEUTICS Corp ROTHBLATT MARTINE A Director, Officer OPT+S $564.01 9,500 $5,358,116 40,513
2026-04-08 20:34 2026-04-06 KNSA Kiniksa Pharmaceuticals International, plc Quart Barry D Director OPT+S $50.00 6,901 $345,050 12,546
2026-04-08 20:18 2026-04-07 CYTK CYTOKINETICS INC Malik Fady Ibraham Officer OPT+S $65.11 4,500 $292,985 153,902
2026-04-07 23:55 2026-04-07 ACAD ACADIA PHARMACEUTICALS INC Kihara James Officer OPT+S $22.20 1,030 $22,866 27,865
2026-04-07 23:57 2026-04-07 ACAD ACADIA PHARMACEUTICALS INC Schneyer Mark C. Officer OPT+S $22.20 2,709 $60,140 62,836
2026-04-07 22:27 2026-04-07 LPCN Lipocine Inc. Higuchi John W. Director BUY $2.03 40,000 $81,200 203,797
2026-04-07 22:17 2026-04-06 TVTX Travere Therapeutics, Inc. Baynes Roy D. Director OPT+S $33.00 10,000 $330,000 37,500
2026-04-07 20:35 2026-04-06 UTHR UNITED THERAPEUTICS Corp ROTHBLATT MARTINE A Director, Officer OPT+S $558.41 9,500 $5,304,905 40,513
2026-04-07 20:35 2026-04-06 UTHR UNITED THERAPEUTICS Corp EDGEMOND JAMES Officer OPT+S $558.40 10,000 $5,583,999 18,876
2026-04-07 20:21 2026-04-02 ALNY ALNYLAM PHARMACEUTICALS, INC. McLaughlin Melissa Officer SELL $325.92 3,910 $1,274,343 9,443
2026-04-07 00:55 2026-04-02 NTHI NEONC TECHNOLOGIES HOLDINGS, INC. Heshmatpour Amir F Director, Officer, 10% owner BUY $6.14 25,000 $153,398 3,017,000
2026-04-06 23:56 2026-04-06 ALKS Alkermes plc. Gaffin David Joseph Officer SELL $34.57 2,034 $70,315 233,592
2026-04-06 23:01 2026-04-06 LPCN Lipocine Inc. Higuchi John W. Director BUY $2.05 123,000 $252,150 163,797
2026-04-06 22:30 2026-04-02 BCYC BICYCLE THERAPEUTICS PLC Skynner Michael Officer SELL $4.94 2,404 $11,877 159,562
2026-04-06 22:30 2026-04-02 BCYC BICYCLE THERAPEUTICS PLC Lee Kevin Director, Officer SELL $4.94 7,683 $37,964 611,313
2026-04-06 22:30 2026-04-02 BCYC BICYCLE THERAPEUTICS PLC Perry Jennifer Scott Officer SELL $4.94 1,408 $6,962 92,464
2026-04-06 22:30 2026-04-02 BCYC BICYCLE THERAPEUTICS PLC Thompson Travis Alvin Officer SELL $4.93 901 $4,438 65,364
2026-04-06 22:30 2026-04-02 BCYC BICYCLE THERAPEUTICS PLC Hannay Michael Charles Ferguson Officer SELL $4.93 1,772 $8,736 96,136
2026-04-06 22:33 2026-04-06 LPCN Lipocine Inc. Patel Mahesh V. Director, Officer BUY $2.03 25,000 $50,750 160,679
2026-04-06 21:43 2026-04-06 CTNM Contineum Therapeutics, Inc. Lorrain Daniel S. Officer SELL $13.43 4,170 $56,014 147,712
2026-04-06 21:32 2026-04-02 CLNN Clene Inc. Ugwumba Chidozie 10% owner SELL $4.81 24,925 $119,889 401,891
2026-04-06 21:20 2026-04-02 PTCT PTC THERAPEUTICS, INC. Golden Lee Scott Officer SELL $67.99 829 $56,364 79,115
2026-04-06 20:41 2026-04-02 UTHR UNITED THERAPEUTICS Corp EDGEMOND JAMES Officer OPT+S $561.50 10,000 $5,614,984 18,876
2026-04-06 20:42 2026-04-02 UTHR UNITED THERAPEUTICS Corp ROTHBLATT MARTINE A Director, Officer OPT+S $561.37 9,500 $5,333,053 40,513
2026-04-06 20:07 2026-04-02 AGIO AGIOS PHARMACEUTICALS, INC. Milanova Tsveta Officer OPT+S $34.71 3,262 $113,224 46,829
2026-04-06 20:08 2026-04-02 AGIO AGIOS PHARMACEUTICALS, INC. Jones Cecilia Officer OPT+S $34.71 3,141 $109,024 54,998
2026-04-06 20:10 2026-04-02 AGIO AGIOS PHARMACEUTICALS, INC. Gheuens Sarah Officer OPT+S $34.71 2,940 $102,047 80,277
2026-04-06 20:11 2026-04-02 AGIO AGIOS PHARMACEUTICALS, INC. Burns James William Officer OPT+S $34.71 3,280 $113,849 49,306
2026-04-06 20:04 2026-04-02 AGIO AGIOS PHARMACEUTICALS, INC. Goff Brian Director, Officer OPT+S $34.71 19,068 $661,850 184,508
2026-04-06 20:05 2026-04-06 ALT Altimmune, Inc. GILL JOHN Director BUY $3.41 9,200 $31,350 21,700
2026-04-06 20:05 2026-04-02 AGIO AGIOS PHARMACEUTICALS, INC. Viswanadhan Krishnan Officer OPT+S $34.71 2,959 $102,707 10,282
SHOW ENTRIES

Sector-Wide Insider Alpha

Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.

SEC Filings in Pharmaceutical Preparations

Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.

UNDERSTANDING THE DATA

FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.

TRADE DATE: The actual day the insider executed the purchase or sale in the market.

INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.

OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.

CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.

TRADE TYPES DEFINITIONS

BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.

SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.

OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.